us government and bitcoin- Top Block

Zhendong Pharmaceutical has set up a new health management service company. The enterprise search APP shows that recently, Shanxi Zhendong Health Management Service Co., Ltd. was established, with Zhao Jin as the legal representative and a registered capital of 10 million yuan. Its business scope includes: remote health management services; Health consulting services (excluding medical services), etc. Enterprise investigation shows that the company is wholly owned by Zhendong Pharmaceutical.The new CEO of Pakistan Stock Exchange said that the exchange is seeking to provide traders with the option of cash settlement of futures trading, and plans to conduct a test before March next year.The cultural media sector rose and strengthened, with more than 10 daily limit shares, including Tianyu Digital, Guangbo, Palm Reading Technology, vision china, Huizhou Intelligent, Guangdong Media, Tianxiaxiu and Lingnan.

Jinshanyun's information technology company increased its capital to USD 500 million. Tianyancha App shows that Jinshan Yun (Hainan Yangpu) Information Technology Co., Ltd. has undergone industrial and commercial changes recently, and its registered capital has increased from USD 400 million to USD 500 million. The company was established in August 2022, and its legal representative is Zou Tao. Its business scope is Internet domain name registration service, computer software and hardware and auxiliary equipment wholesale, technical service, technical development, technical consultation, technical exchange, technology transfer, technology promotion, information system integration service, software development and software sales, and it is wholly owned by Jinshanyun Co., Ltd.Ha Sanlian: Four kinds of drugs are planned to win the bid for national centralized procurement. Ha Sanlian announced that the company and its wholly-owned subsidiary Lanxi Pharmaceutical participated in the tenth batch of national centralized procurement of drugs organized by the state. The company's esmolol hydrochloride injection, pentoxifylline injection, potassium chloride injection, and tandospirone citrate tablets of Lanxi Pharmaceutical intend to win the bid for this centralized procurement. If the subsequent purchase contract is signed and implemented, it will help to expand the sales of related products and improve the market share and brand influence. The prices of the above-mentioned drugs are respectively 1.34 yuan for esmolol hydrochloride injection, 0.59 yuan for pentoxifylline injection, 0.16 yuan for potassium chloride injection and 6.56 yuan for tandospirone citrate tablets.On the 13th, coking coal fell by 2.15%, and the latest main contract positions changed as follows. According to the exchange data, as of December 13th, the main contract coking coal closed at 2501, up or down by -2.15%, with a turnover of 104,800 lots. The position data showed that the top 20 seats were clear, and the difference position was 15,553 lots. The total contract turnover of coking coal futures was 180,200 lots, an increase of 8,845 lots over the previous day. The first 20 seats in the contract held 163,200 lots, an increase of 4,563 lots over the previous day. The short positions in the top 20 seats of the contract were 194,300 lots, an increase of 5,926 lots over the previous day. (Sina Futures)

The concept of robot bottomed out and Tianqi shares rose linearly, and Tianqi shares rose linearly. Before that, the construction industry went out of 9 boards in 10 days, Astar went out of 13 boards in 21 days, and Tongda Power went up. Hanyu Group, Maihe, Jiangsu Reilly, Hanwei Technology and Best were among the top gainers.Chen Guo, China Securities: The 2025 policy will focus on expanding domestic demand and AI+ in all directions, and the Central Economic Work Conference will be held in Beijing from December 11th to 12th. Chen Guo, chief strategy officer of China Securities, said that the meeting had seven highlights, including clarifying the growth target and fiscal and monetary policy measures, expanding domestic demand in all directions as the top priority of the policy, focusing on "AI+" in science and technology, focusing on implementation of reform measures, paying attention to coping with external shocks in opening up, strengthening the expression of real estate policies, and increasing efforts to improve people's livelihood. Chen Guo said that further RRR cuts and interest rate cuts from the end of 2024 to 2025 are worth looking forward to, and the easing of the liquidity environment has become a market consensus. However, this does not mean that liquidity is rampant, because the growth of money supply in the scale of social financing still continues the requirement of matching the expected target of the overall price level of economic growth. Chen Guo believes that the 2025 policy will focus on expanding domestic demand and AI+ in an all-round way, and the strength and direction of the policy are in line with expectations. With the support of policy expectations and liquidity, it is expected that the market will continue to show the characteristics of volatility. From the perspective of investment strategy, Chen Guo suggested focusing on non-bank finance, real estate chain, consumer electronics, machinery, construction, building materials, steel, social services, catering chain and other sectors. In terms of theme, it is suggested to pay attention to investment opportunities such as "duality" and "two innovations", supply-side optimization, new quality productivity, market value management of state-owned enterprises and CSI A500 index.Asia-Pacific Pharmaceuticals: The new specifications of cefmetazole sodium for injection were approved, and Asia-Pacific Pharmaceuticals announced that the company was approved by National Medical Products Administration, and the new specifications of cefmetazole sodium for injection were 0.5g and 2g, which further enriched the product categories on the basis of the original 1g specifications. The annual sales income of this drug in 2023 was 96.3946 million yuan, accounting for 22.92% of the company's operating income. New specifications are helpful to market promotion and competitiveness improvement, but drug production and sales are affected by policies and market environment, and there are uncertainties.